心房颤动射频消融围术期的抗凝治疗进展  

Progress in Anticoagulation Therapy in the Perioperative Period of Catheter Ablation for Patients with Atrial Fibrillation

作　　者：杨尚珂 赵强[1] YANG Shangke;ZHAO Qiang(Department of Cardiology,the Red Cross Hospital of Guangzhou City Affiliated to Jinan University,Guangzhou 510220,China)

机构地区：[1]暨南大学附属广州红十字会医院心血管内科,广州510220

出　　处：《医学综述》2018年第5期931-935,940,共6页Medical Recapitulate

摘　　要：心房颤动(房颤)是常见的心律失常,随着年龄的增长,房颤的发生率也随之增加,目前射频消融术已成为房颤的一线治疗方案。射频消融术在围术期存在着栓塞事件、大出血事件、小出血事件等并发症,如何选择安全有效的抗凝方案对于减少围术期并发症的发生尤为重要。传统的抗凝方案为肝素桥接法,而不中断华法林法、口服新型抗凝药等新型抗凝方案的安全性及有效性也逐渐被证实并广泛采用。Atrial fibrillation is a common arrthymia,and the incidence of atrial fibrillation increases with age grows.Catheter ablation is recommended as a first-line treatment for patients with atrial fibrillation.On account of the periproce-dural complications such as embolic events,major bleeding and minor bleeding events,selecting the right anticoagulation method for patients undergoing atrial fibrillation ablation is particularly important to minimize complications.The traditional anticoagulation strategy is heparin bridging.There is growing evidence showing that uninterrupted warfarin and new oral anticoagulants are safe and effective.

关 键 词：心房颤动 射频消融 华法林 新型口服抗凝药 

分 类 号：R541.75[医药卫生—心血管疾病]